- Home
- ANGO vs HQL Comparison
ANGO vs HQL Comparison
Compare ANGO & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- HQL
- Stock Information
- Founded
- ANGO 1988
- HQL 1992
- Country
- ANGO United States
- HQL United States
- Employees
- ANGO N/A
- HQL N/A
- Industry
- ANGO Medical/Dental Instruments
- HQL Investment Managers
- Sector
- ANGO Health Care
- HQL Finance
- Exchange
- ANGO Nasdaq
- HQL Nasdaq
- Market Cap
- ANGO 439.5M
- HQL 368.7M
- IPO Year
- ANGO 2004
- HQL N/A
- Fundamental
- Price
- ANGO $9.52
- HQL $11.82
- Analyst Decision
- ANGO Strong Buy
- HQL
- Analyst Count
- ANGO 2
- HQL 0
- Target Price
- ANGO $14.00
- HQL N/A
- AVG Volume (30 Days)
- ANGO 674.1K
- HQL 120.9K
- Earning Date
- ANGO 04-02-2025
- HQL 01-01-0001
- Dividend Yield
- ANGO N/A
- HQL 11.56%
- EPS Growth
- ANGO N/A
- HQL N/A
- EPS
- ANGO N/A
- HQL 0.79
- Revenue
- ANGO $283,320,000.00
- HQL N/A
- Revenue This Year
- ANGO N/A
- HQL N/A
- Revenue Next Year
- ANGO $6.35
- HQL N/A
- P/E Ratio
- ANGO N/A
- HQL $17.08
- Revenue Growth
- ANGO N/A
- HQL N/A
- 52 Week Low
- ANGO $5.47
- HQL $11.34
- 52 Week High
- ANGO $13.50
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- ANGO 48.91
- HQL 42.79
- Support Level
- ANGO $9.26
- HQL $11.59
- Resistance Level
- ANGO $9.94
- HQL $11.93
- Average True Range (ATR)
- ANGO 0.65
- HQL 0.42
- MACD
- ANGO 0.01
- HQL 0.03
- Stochastic Oscillator
- ANGO 26.17
- HQL 56.95
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.